advances in the teatment of high-risk early-stage hormone receptor positive breast cancer
Published 6 months ago • 119 plays • Length 4:01Download video MP4
Download video MP3
Similar videos
-
1:30
exploring endocrine therapy innovations for high-risk hormone receptor-positive breast cancer
-
2:35
treatment options for high risk early breast cancer
-
1:23
latest advances in immuno-oncology research in er breast cancer
-
3:05
advancements in immunotherapy for high-risk hr breast cancer
-
7:05
late recurrences in er-positive breast cancer and the challenges it poses for treatment
-
2:30
monarche: abemaciclib and adjuvant endocrine therapy for high-risk hr early breast cancer
-
1:26
monarche: investigating adjuvant abemacicilib for high-risk hr breast cancer
-
4:07
new advances in hormonal therapies for er-positive breast cancer
-
1:01
future of breast cancer care: her2 therapies in earlier settings & de-escalation
-
4:12
optimizing treatment in patients with early-stage her2-positive breast cancer
-
2:55
e2112: endocrine therapy plus entinostat in hr advanced breast cancer
-
0:52
first-line camizestrant for er /her2- advanced breast cancer
-
3:44
alternate: neoadjuvant endocrine treatment in er /her2- breast cancer
-
0:36
endocrine therapy and cdk4/6 inhibitors in high-risk hr breast cancer
-
1:19
optimizing adjuvant therapy: chemotherapy necessity in hr-positive breast cancer
-
4:03
monarche 4-year: abemaciclib endocrine therapy for hr , her2-, node-positive, high-risk early bc
-
1:22
her2dx risk-score in early-stage her2-positive breast cancer
-
5:06
safety outcomes in the phase iii monarche trial of abemaciclib et in hr , her2- breast cancer
-
2:06
unmet needs and cdk4/6 inhibitors in hr /her2- early breast cancer